Peptide Receptor Radionuclide Therapy (PRRT) for the Treatment of Neuroendocrine Tumors

Description

The specific aim is of this study is to gain a better understanding of the patient characteristics, treatment responses, survival outcomes, and adverse events associated with PRRT in patients with gastroenteropancreatic primary NETs.

Conditions

Neuroendocrine Tumors

Talk to us

Study Overview

On this page

Study Details

Study overview

The specific aim is of this study is to gain a better understanding of the patient characteristics, treatment responses, survival outcomes, and adverse events associated with PRRT in patients with gastroenteropancreatic primary NETs.

Peptide Receptor Radionuclide Therapy (PRRT) for the Treatment of Neuroendocrine

Peptide Receptor Radionuclide Therapy (PRRT) for the Treatment of Neuroendocrine Tumors

Condition
Neuroendocrine Tumors
Intervention / Treatment

-

Contacts and Locations

Dallas

Clinical Research Institute at Methodist Health System, Dallas, Texas, United States, 75203

Dallas

Methodist Dallas Medical Center, Dallas, Texas, United States, 75203

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. \> 18 years of age
  • 2. Diagnosed with gastroenteropancreatic primary NET and has consented to undergo PRRT per the treating physician. Specifically:
  • * Will consider other primaries on a case by case basis if dotatate scan (+) and meet all other criteria.
  • * Metastatic or Locally Advanced AND Inoperable
  • * Clear disease progression on Octreotide over less than 3 years (RECIST 1.1)
  • * Presence of disease within 24 weeks as identified by PET/CT scans with Ga-68 DOTATATE reporting the Krenning score for low-grade NET and/or PET/CT scans with FDG for transformation to high-grade NET
  • * Well differentiated on path - Ki67 \< 20%
  • * Octreotide positive on pathology (if not documented, acceptable if PET/CT imaging shows lesions with Ga-68 DOTATATE uptakeLabs:
  • * Cr. \<1.7
  • * Hgb \>8
  • * WBC \>2K
  • * Plt \>75K
  • * Bili \< 3x normal limit
  • * No Octreotide within 30 days of administration.
  • 3. Willing and able to comply with the protocol requirements
  • 4. Able to comprehend and sign the Informed Consent Form in English.
  • * Do not meet the Study Inclusion Criteria laid out in section 6.3

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Methodist Health System,

Alejandro Mejia, MD, PRINCIPAL_INVESTIGATOR, Liver Institute at Methodist Dallas Medical Center

Study Record Dates

2024-06-28